GeneDx (WGSWW) Stock Price, News & Analysis

Company Overview

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

Key Stats

• Today's Range: $0.06 to $0.08
• 50-Day Range: $0.06 to $0.29
• 52-Week Range: $0.02 to $0.34
• Volume: 111,104 shs
• Average Volume: 43,530 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

WGSWW Stock Analysis - Frequently Asked Questions

How have WGSWW shares performed this year?

GeneDx's stock was trading at $0.16 at the beginning of 2025. Since then, WGSWW shares have decreased by 60.4% and is now trading at $0.0634.
View the best growth stocks for 2025 here.

How do I buy shares of GeneDx?

Shares of WGSWW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: NASDAQ:WGSWW
• CIK: 1818331
• Web: www.genedx.com
• Phone: 800-298-6470
• Fax: N/A
• Employees: 1,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $330.14 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A